COMPUMED, INC. SELECTS SCHILLER AG DATA PLATFORM FOR REMOTE ECG SYSTEM UPGRADE
Internet-Optimized CardioGram(TM) Will Improve and Expand International Remote ECG Interpretation Capabilities

LOS ANGELES, July 13, 2004 -- CompuMed, Inc. (CMPD.OB) -- a medical informatics company serving the healthcare community with diagnostic software solutions -- today announced that it has selected global patient monitoring/data acquisition systems leader Schiller AG to provide a new server platform and terminals for its upgraded CardioGram remote electrocardiograph (ECG) product line.

Based in Baar, Switzerland, Schiller is the world's leader in electrocardiograph sales, capturing approximately 60% of the market. Schiller is customizing its new Sem@Net data management solution to meet CompuMed's specifications as the new platform for its CardioGram remote ECG interpretation system.

"We are very pleased to announce our partnership with Schiller," said Jerry McLaughlin, CompuMed's CEO. "Schiller's sophisticated server platform and highly advanced Internet-enabled ECG terminals are an ideal fit with our expansion into international markets."

CompuMed's traditional core business is providing remote ECG interpretation services to medical facilities that may not have access to trained physicians qualified to interpret ECG results. Customers for the Company's CardioGram system are typically ambulatory surgery centers, occupational health clinics, physicians' offices and correctional facilities. One of the Cardiogram's many advantages is an optional feature that automatically sends ECG results to a trained cardiologist for an overread when the results are abnormal.

With heart disease as the number one cause of death worldwide, CompuMed has been exploring opportunities to launch its CardioGram service overseas. The Company believes that an overread by an American cardiologist could be a value-added service in countries where cardiologists are not readily available.

About CompuMed:

Founded in 1973, CompuMed, Inc. (OTC Bulletin Board: CMPD) is a leading provider of computer-aided telemedicine and diagnostics technology. The company's core products are the OsteoGramŽ and CardioGram systems. The OsteoGram, which is cleared by the FDA for commercial use, is an accurate and precise technology for low-cost osteoporosis testing. The CardioGram system remotely interprets electrocardiograms and is used by private practice, government and corporate healthcare providers nationwide. The CardioGram also has the capability to automatically provide an over-read (i.e., follow-up review) by a cardiologist. CompuMed is headquartered in Los Angeles. Visit CompuMed at www.compumed.net.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks defined in this document. All such forward-looking statements whether written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

CONTACT: Erik Deutsch - Tellem Worldwide, +1 (310) 479-6111 x.15, edeutsch@tellem.com